Contrasting American Renal Associates (NYSE:ARA) & Progyny (NYSE:PGNY)

American Renal Associates (NYSE:ARA) and Progyny (NASDAQ:PGNY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of recent ratings for American Renal Associates and Progyny, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
American Renal Associates 0 6 0 0 2.00
Progyny 0 0 6 0 3.00

American Renal Associates currently has a consensus target price of $10.33, indicating a potential upside of 9.23%. Progyny has a consensus target price of $29.67, indicating a potential upside of 11.36%. Given Progyny’s stronger consensus rating and higher probable upside, analysts plainly believe Progyny is more favorable than American Renal Associates.

Valuation and Earnings

This table compares American Renal Associates and Progyny’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
American Renal Associates $805.78 million 0.38 -$28.77 million N/A N/A
Progyny $105.40 million 20.77 N/A N/A N/A

Progyny has lower revenue, but higher earnings than American Renal Associates.

Insider and Institutional Ownership

85.4% of American Renal Associates shares are held by institutional investors. 9.4% of American Renal Associates shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


This table compares American Renal Associates and Progyny’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
American Renal Associates -1.75% 23.16% 2.04%
Progyny N/A N/A N/A

American Renal Associates Company Profile

American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of June 30, 2018, it owned and operated 233 dialysis clinics in partnership with 400 nephrologist partners treating approximately 16,000 patients in 26 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.

Progyny Company Profile

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption expenses for clients and their employees. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit